• Thumbnail for HER2
    family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration...
    43 KB (4,651 words) - 13:41, 27 July 2024
  • Thumbnail for Trastuzumab deruxtecan
    epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized...
    25 KB (2,086 words) - 02:24, 16 July 2024
  • Thumbnail for Trastuzumab
    breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy...
    69 KB (6,048 words) - 05:15, 1 October 2024
  • Thumbnail for Pertuzumab
    the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. Side...
    24 KB (2,276 words) - 04:42, 1 October 2024
  • Thumbnail for Trastuzumab emtansine
    agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization...
    29 KB (2,696 words) - 14:16, 27 July 2024
  • Thumbnail for Breast cancer
    Breast cancer (redirect from HER2 negative)
    20% of tumors contain HER2; these can be treated with HER2-targeted therapies. The remainder that do not contain ER, PR, or HER2 are called "triple-negative"...
    135 KB (15,182 words) - 13:39, 15 October 2024
  • positive (HER2+), and HER2 negative (HER2-). Cells with none of these receptors are called basal-like or triple negative. HER2-low has some HER2 proteins...
    92 KB (9,503 words) - 14:29, 12 August 2024
  • progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on...
    28 KB (3,411 words) - 03:40, 14 June 2024
  • Thumbnail for Inavolisib
    hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an...
    20 KB (1,717 words) - 23:41, 14 October 2024
  • treat adults with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adults with early HER2-positive breast cancer...
    12 KB (966 words) - 04:46, 15 July 2024
  • Center in 1970 that is used in therapeutic research, especially in context of HER2 targeting. SkBr3 cells were derived from a pleural effusion due to an adenocarcinoma...
    3 KB (363 words) - 01:24, 3 December 2023
  • Thumbnail for Lapatinib
    which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer...
    18 KB (1,504 words) - 01:24, 12 October 2024
  • Thumbnail for Abemaciclib
    hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after...
    18 KB (1,467 words) - 23:44, 20 August 2024
  • Thumbnail for Palbociclib
    is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent...
    37 KB (3,558 words) - 20:55, 20 August 2024
  • In HER2 overexpressing breast cancers, the HER2–IL-6–STAT3 signaling relationship could be targeted to develop new therapeutic strategies. HER2 kinase...
    18 KB (2,105 words) - 01:40, 20 August 2024
  • Thumbnail for Ann Marie Rogers
    whose tumors have too much HER2 protein. This type of cancer is known as "HER2-positive", "HER2+", or "HER2 overexpressing". HER2+ tumors tend to grow and...
    4 KB (337 words) - 20:15, 26 September 2024
  • Thumbnail for Tucatinib
    anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and...
    21 KB (1,685 words) - 05:17, 16 July 2024
  • Thumbnail for Vosilasarm
    the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was also previously under development...
    27 KB (2,530 words) - 11:05, 5 March 2024
  • Thumbnail for Afatinib
    that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only...
    15 KB (1,122 words) - 15:16, 4 August 2024
  • Thumbnail for Dalpiciclib
    approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed...
    4 KB (141 words) - 22:46, 5 August 2024
  • Thumbnail for Ribociclib
    hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase...
    18 KB (1,588 words) - 05:26, 15 October 2024
  • Thumbnail for Neratinib
    of adults with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting...
    16 KB (1,300 words) - 02:35, 16 July 2024
  • Thumbnail for Antibody–drug conjugate
    and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment...
    41 KB (4,305 words) - 11:56, 24 August 2024
  • early and advanced (metastatic) HER2+ breast cancer as well as advanced (metastatic) stomach cancer. Herzuma is a HER2+ breast cancer therapy designed...
    11 KB (695 words) - 18:51, 8 October 2024
  • Thumbnail for Buparlisib
    Buparlisib was under investigation as a treatment for advanced or metastatic HER2-negative breast cancer in several phase III clinical trials: The phase III...
    8 KB (690 words) - 22:44, 5 August 2024
  • Thumbnail for Heterogeneous ribonucleoprotein particle
    induce cell-cycle arrest in response to DNA damage by ionizing radiation. HER2 is overexpressed in 20-30% of breast cancers and is commonly associated with...
    17 KB (2,028 words) - 04:21, 17 June 2024
  • Thumbnail for Vepdegestrant
    patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study". Annals...
    4 KB (173 words) - 18:16, 22 April 2024
  • Thumbnail for ALK inhibitor
    alectinib+cobimetinib. Results for the last two are expected around 2020-2021. The EGFR and HER2 pathways are commonly abnormally activated in a large proportion of cancers...
    17 KB (1,951 words) - 10:39, 25 January 2024
  • HER2 gene. Recently approved for adjuvant therapy for breast cancer. FDA also recently approved Trastuzumab for metastatic gastric cancer with HER2 receptor...
    32 KB (2,865 words) - 04:21, 4 October 2024
  • immunohistochemistry staining machine for microscopy slides to highlight HER2 expression. This machine is classified by the U.S. Food and Drug Administration...
    5 KB (363 words) - 16:08, 13 December 2023